Enliven Therapeutics, Inc. (NASDAQ: ELVN) Stock Competitors & Peer Comparison
See ELVN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ELVN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ELVN | $49.43 | +10.36% | 3.6B | -29.63 | -$1.67 | N/A |
| VRTX | $547.09 | +0.85% | 138.6B | 28.74 | $19.03 | N/A |
| MRNA | $254.19 | +5.27% | 101.5B | -31.20 | -$8.15 | N/A |
| REGN | $904.35 | +0.16% | 93.6B | 19.82 | $45.63 | +0.41% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $927.21 | +3.63% | 55.3B | 33.44 | $27.73 | N/A |
| ONC | $406.96 | +5.09% | 43.5B | 71.66 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.90 | +16.47% | 41.4B | -1.12 | -$8.82 | N/A |
| RVMD | $192.28 | +8.24% | 41.2B | -21.79 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ELVN vs VRTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, VRTX has a market cap of 138.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while VRTX trades at $547.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas VRTX's P/E ratio is 28.74. In terms of profitability, ELVN's ROE is -0.17%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, ELVN is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ELVN vs MRNA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MRNA has a market cap of 101.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MRNA trades at $254.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MRNA's P/E ratio is -31.20. In terms of profitability, ELVN's ROE is -0.17%, compared to MRNA's ROE of -0.38%. Regarding short-term risk, ELVN is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ELVN vs REGN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, REGN has a market cap of 93.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while REGN trades at $904.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas REGN's P/E ratio is 19.82. In terms of profitability, ELVN's ROE is -0.17%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ELVN is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ELVN vs VRNA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ELVN's ROE is -0.17%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ELVN is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ELVN vs ARGX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ARGX has a market cap of 55.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ARGX trades at $927.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ARGX's P/E ratio is 33.44. In terms of profitability, ELVN's ROE is -0.17%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, ELVN is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
ELVN vs ONC Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ONC has a market cap of 43.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ONC trades at $406.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ONC's P/E ratio is 71.66. In terms of profitability, ELVN's ROE is -0.17%, compared to ONC's ROE of +0.18%. Regarding short-term risk, ELVN is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
ELVN vs SGEN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ELVN's ROE is -0.17%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ELVN is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ELVN vs RVMDW Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RVMDW has a market cap of 41.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RVMDW trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RVMDW's P/E ratio is -1.12. In terms of profitability, ELVN's ROE is -0.17%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, ELVN is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ELVN vs RVMD Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RVMD has a market cap of 41.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RVMD trades at $192.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RVMD's P/E ratio is -21.79. In terms of profitability, ELVN's ROE is -0.17%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, ELVN is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RVMD's competition here
Genmab A/S (NASDAQ: GMAB)
ELVN vs GMAB Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, GMAB has a market cap of 33B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while GMAB trades at $53.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas GMAB's P/E ratio is 40.41. In terms of profitability, ELVN's ROE is -0.17%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ELVN is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ELVN vs ROIV Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ROIV has a market cap of 28.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ROIV trades at $38.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ROIV's P/E ratio is -37.00. In terms of profitability, ELVN's ROE is -0.17%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ELVN is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
ELVN vs INSM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, INSM has a market cap of 25.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while INSM trades at $114.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas INSM's P/E ratio is -40.59. In terms of profitability, ELVN's ROE is -0.17%, compared to INSM's ROE of -0.83%. Regarding short-term risk, ELVN is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
ELVN vs INCY Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, INCY has a market cap of 24.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while INCY trades at $119.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas INCY's P/E ratio is 16.08. In terms of profitability, ELVN's ROE is -0.17%, compared to INCY's ROE of +0.07%. Regarding short-term risk, ELVN is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ELVN vs UTHR Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, UTHR has a market cap of 24.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while UTHR trades at $562.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas UTHR's P/E ratio is 20.11. In terms of profitability, ELVN's ROE is -0.17%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ELVN is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check UTHR's competition here
BioNTech SE (NASDAQ: BNTX)
ELVN vs BNTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BNTX has a market cap of 21.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BNTX trades at $87.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BNTX's P/E ratio is -11.35. In terms of profitability, ELVN's ROE is -0.17%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, ELVN is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BNTX's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ELVN vs ALNY Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ALNY has a market cap of 20.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ALNY trades at $155.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ALNY's P/E ratio is 7.87. In terms of profitability, ELVN's ROE is -0.17%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, ELVN is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ALNY's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ELVN vs BGNE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ELVN's ROE is -0.17%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, ELVN is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ELVN vs DNA-WT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ELVN's ROE is -0.17%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, ELVN is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ELVN vs EXEL Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, EXEL has a market cap of 17.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while EXEL trades at $69.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas EXEL's P/E ratio is 19.87. In terms of profitability, ELVN's ROE is -0.17%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, ELVN is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ELVN vs ASND Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ASND has a market cap of 16.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ASND trades at $256.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ASND's P/E ratio is -106.12. In terms of profitability, ELVN's ROE is -0.17%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ELVN is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ELVN vs NBIX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, NBIX has a market cap of 16.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while NBIX trades at $164.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas NBIX's P/E ratio is 23.79. In terms of profitability, ELVN's ROE is -0.17%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, ELVN is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ELVN vs JAZZ Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, JAZZ has a market cap of 15.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while JAZZ trades at $234.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas JAZZ's P/E ratio is 8.75. In terms of profitability, ELVN's ROE is -0.17%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, ELVN is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ELVN vs BBIO Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BBIO has a market cap of 14.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BBIO trades at $74.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BBIO's P/E ratio is -24.43. In terms of profitability, ELVN's ROE is -0.17%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, ELVN is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ELVN vs SMMT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, SMMT has a market cap of 13B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while SMMT trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas SMMT's P/E ratio is -14.58. In terms of profitability, ELVN's ROE is -0.17%, compared to SMMT's ROE of -1.59%. Regarding short-term risk, ELVN is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ELVN vs KRTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ELVN's ROE is -0.17%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ELVN is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ELVN vs HALO Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, HALO has a market cap of 11.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while HALO trades at $103.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas HALO's P/E ratio is 19.35. In terms of profitability, ELVN's ROE is -0.17%, compared to HALO's ROE of +5.44%. Regarding short-term risk, ELVN is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check HALO's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ELVN vs TECH Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TECH trades at $72.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TECH's P/E ratio is 37.52. In terms of profitability, ELVN's ROE is -0.17%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ELVN is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ELVN vs RNAM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ELVN's ROE is -0.17%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ELVN is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RNAM's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ELVN vs KYMR Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, KYMR has a market cap of 11.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while KYMR trades at $131.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas KYMR's P/E ratio is -36.38. In terms of profitability, ELVN's ROE is -0.17%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ELVN is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check KYMR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ELVN vs BMRN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BMRN trades at $56.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BMRN's P/E ratio is 26.93. In terms of profitability, ELVN's ROE is -0.17%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, ELVN is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BMRN's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ELVN vs PCVX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while PCVX trades at $63.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas PCVX's P/E ratio is -8.37. In terms of profitability, ELVN's ROE is -0.17%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, ELVN is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check PCVX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ELVN vs SYRE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, SYRE has a market cap of 9.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while SYRE trades at $103.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas SYRE's P/E ratio is -53.26. In terms of profitability, ELVN's ROE is -0.17%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, ELVN is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check SYRE's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ELVN vs RXDX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ELVN's ROE is -0.17%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ELVN is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RXDX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ELVN vs MDGL Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MDGL trades at $399.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MDGL's P/E ratio is -31.27. In terms of profitability, ELVN's ROE is -0.17%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, ELVN is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MDGL's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ELVN vs TGTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TGTX has a market cap of 9.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TGTX trades at $59.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TGTX's P/E ratio is 21.68. In terms of profitability, ELVN's ROE is -0.17%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ELVN is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check TGTX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ELVN vs IBRX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, IBRX has a market cap of 9.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while IBRX trades at $8.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas IBRX's P/E ratio is -8.90. In terms of profitability, ELVN's ROE is -0.17%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ELVN is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ELVN vs NUVL Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ELVN's ROE is -0.17%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ELVN is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ELVN vs CRNX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ELVN's ROE is -0.17%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ELVN is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CRNX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ELVN vs KRYS Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, KRYS has a market cap of 8.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while KRYS trades at $300.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas KRYS's P/E ratio is 37.68. In terms of profitability, ELVN's ROE is -0.17%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, ELVN is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check KRYS's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ELVN vs IMGN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ELVN's ROE is -0.17%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ELVN is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ELVN vs PTGX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while PTGX trades at $132.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas PTGX's P/E ratio is 128.05. In terms of profitability, ELVN's ROE is -0.17%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, ELVN is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ELVN vs APGE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas APGE's P/E ratio is -31.19. In terms of profitability, ELVN's ROE is -0.17%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ELVN is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ELVN vs BPMC Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ELVN's ROE is -0.17%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ELVN is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BPMC's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ELVN vs ARWR Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ARWR has a market cap of 8.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ARWR trades at $58.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ARWR's P/E ratio is -25.84. In terms of profitability, ELVN's ROE is -0.17%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ELVN is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ELVN vs CERE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CERE's P/E ratio is -16.47. In terms of profitability, ELVN's ROE is -0.17%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ELVN is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CERE's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ELVN vs TWST Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TWST has a market cap of 8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TWST trades at $120.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TWST's P/E ratio is -54.47. In terms of profitability, ELVN's ROE is -0.17%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ELVN is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check TWST's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ELVN vs PRAX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while PRAX trades at $277.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas PRAX's P/E ratio is -21.49. In terms of profitability, ELVN's ROE is -0.17%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ELVN is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check PRAX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ELVN vs RYTM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RYTM has a market cap of 7.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RYTM trades at $112.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RYTM's P/E ratio is -36.07. In terms of profitability, ELVN's ROE is -0.17%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, ELVN is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RYTM's competition here
Abivax S.A. (NASDAQ: ABVX)
ELVN vs ABVX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ABVX trades at $85.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ABVX's P/E ratio is -14.06. In terms of profitability, ELVN's ROE is -0.17%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ELVN is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ABVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ELVN vs CYTK Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CYTK has a market cap of 7.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CYTK trades at $53.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CYTK's P/E ratio is -7.44. In terms of profitability, ELVN's ROE is -0.17%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, ELVN is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
ELVN vs MTSR Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ELVN's ROE is -0.17%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ELVN is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ELVN vs CAI Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CAI has a market cap of 7.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CAI trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CAI's P/E ratio is 70.92. In terms of profitability, ELVN's ROE is -0.17%, compared to CAI's ROE of +0.16%. Regarding short-term risk, ELVN is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CAI's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ELVN vs TXG Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TXG has a market cap of 7.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TXG trades at $59.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TXG's P/E ratio is -100.53. In terms of profitability, ELVN's ROE is -0.17%, compared to TXG's ROE of -0.08%. Regarding short-term risk, ELVN is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check TXG's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ELVN vs AXSM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, AXSM has a market cap of 7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while AXSM trades at $132.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas AXSM's P/E ratio is -34.56. In terms of profitability, ELVN's ROE is -0.17%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, ELVN is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check AXSM's competition here
Merus N.V. (NASDAQ: MRUS)
ELVN vs MRUS Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ELVN's ROE is -0.17%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ELVN is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MRUS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ELVN vs ORKA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ORKA has a market cap of 6.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ORKA trades at $102.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ORKA's P/E ratio is -52.98. In terms of profitability, ELVN's ROE is -0.17%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ELVN is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ORKA's competition here
CG Oncology Inc. (NASDAQ: CGON)
ELVN vs CGON Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CGON has a market cap of 6.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CGON trades at $75.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CGON's P/E ratio is -28.25. In terms of profitability, ELVN's ROE is -0.17%, compared to CGON's ROE of -0.19%. Regarding short-term risk, ELVN is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check CGON's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ELVN vs ACLX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ELVN's ROE is -0.17%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ELVN is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ELVN vs RETA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RETA's P/E ratio is -66.29. In terms of profitability, ELVN's ROE is -0.17%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ELVN is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RETA's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ELVN vs IONS Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, IONS has a market cap of 6.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while IONS trades at $39.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas IONS's P/E ratio is -12.05. In terms of profitability, ELVN's ROE is -0.17%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ELVN is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check IONS's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ELVN vs IMVT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, IMVT has a market cap of 6.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while IMVT trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas IMVT's P/E ratio is -10.82. In terms of profitability, ELVN's ROE is -0.17%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ELVN is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check IMVT's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ELVN vs CNTA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ELVN's ROE is -0.17%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ELVN is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ELVN vs KOD Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while KOD trades at $99.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas KOD's P/E ratio is -23.82. In terms of profitability, ELVN's ROE is -0.17%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ELVN is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check KOD's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ELVN vs BLTE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while BLTE trades at $154.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas BLTE's P/E ratio is -82.52. In terms of profitability, ELVN's ROE is -0.17%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ELVN is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check BLTE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ELVN vs LGND Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while LGND trades at $306.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas LGND's P/E ratio is 33.58. In terms of profitability, ELVN's ROE is -0.17%, compared to LGND's ROE of +0.05%. Regarding short-term risk, ELVN is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check LGND's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ELVN vs TERN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TERN's P/E ratio is -51.41. In terms of profitability, ELVN's ROE is -0.17%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ELVN is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check TERN's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ELVN vs MIRM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MIRM trades at $93.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MIRM's P/E ratio is -6.44. In terms of profitability, ELVN's ROE is -0.17%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, ELVN is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MIRM's competition here
Veradermics, Incorporated (NYSE: MANE)
ELVN vs MANE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MANE has a market cap of 5.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MANE trades at $138.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MANE's P/E ratio is -44.17. In terms of profitability, ELVN's ROE is -0.17%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ELVN is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MANE's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ELVN vs SRRK Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while SRRK trades at $46.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas SRRK's P/E ratio is -13.60. In terms of profitability, ELVN's ROE is -0.17%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ELVN is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check SRRK's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ELVN vs CDTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ELVN's ROE is -0.17%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ELVN is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
ELVN vs ABCM Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ELVN's ROE is -0.17%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ELVN is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ELVN vs ISEE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ELVN's ROE is -0.17%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ELVN is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ELVN vs COGT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while COGT trades at $31.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas COGT's P/E ratio is -15.00. In terms of profitability, ELVN's ROE is -0.17%, compared to COGT's ROE of -0.71%. Regarding short-term risk, ELVN is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ELVN vs PTCT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, PTCT has a market cap of 5.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while PTCT trades at $65.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas PTCT's P/E ratio is -46.74. In terms of profitability, ELVN's ROE is -0.17%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, ELVN is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check PTCT's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ELVN vs APLS Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas APLS's P/E ratio is 38.35. In terms of profitability, ELVN's ROE is -0.17%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ELVN is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
ELVN vs ERAS Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ERAS has a market cap of 5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ERAS trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ERAS's P/E ratio is -15.49. In terms of profitability, ELVN's ROE is -0.17%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ELVN is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ERAS's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ELVN vs CRSP Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CRSP trades at $50.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CRSP's P/E ratio is -10.52. In terms of profitability, ELVN's ROE is -0.17%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, ELVN is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CRSP's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ELVN vs EWTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while EWTX trades at $45.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas EWTX's P/E ratio is -24.37. In terms of profitability, ELVN's ROE is -0.17%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, ELVN is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check EWTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ELVN vs DNTH Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, DNTH has a market cap of 4.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while DNTH trades at $86.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas DNTH's P/E ratio is -20.72. In terms of profitability, ELVN's ROE is -0.17%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ELVN is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check DNTH's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ELVN vs TVTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TVTX trades at $49.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TVTX's P/E ratio is -110.27. In terms of profitability, ELVN's ROE is -0.17%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, ELVN is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check TVTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ELVN vs FOLD Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ELVN's ROE is -0.17%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ELVN is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ELVN vs AKRO Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ELVN's ROE is -0.17%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ELVN is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check AKRO's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ELVN vs DFTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while DFTX trades at $33.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas DFTX's P/E ratio is N/A. In terms of profitability, ELVN's ROE is -0.17%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ELVN is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check DFTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ELVN vs ADPT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ADPT trades at $27.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ADPT's P/E ratio is -68.20. In terms of profitability, ELVN's ROE is -0.17%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, ELVN is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ELVN vs ALPN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ELVN's ROE is -0.17%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ELVN is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ALPN's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ELVN vs LEGN Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, LEGN has a market cap of 4.3B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while LEGN trades at $23.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas LEGN's P/E ratio is -34.41. In terms of profitability, ELVN's ROE is -0.17%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ELVN is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check LEGN's competition here
Opthea Limited (NASDAQ: OPT)
ELVN vs OPT Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas OPT's P/E ratio is -1.52. In terms of profitability, ELVN's ROE is -0.17%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ELVN is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ELVN vs PRTC Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ELVN's ROE is -0.17%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ELVN is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ELVN vs MRTX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ELVN's ROE is -0.17%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ELVN is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ELVN vs RLAY Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RLAY trades at $18.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RLAY's P/E ratio is -11.85. In terms of profitability, ELVN's ROE is -0.17%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, ELVN is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for ELVN.Check RLAY's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ELVN vs CPRX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ELVN's ROE is -0.17%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ELVN is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ELVN vs ABCL Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ABCL trades at $11.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ABCL's P/E ratio is -22.01. In terms of profitability, ELVN's ROE is -0.17%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ELVN is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ABCL's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ELVN vs XENE Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while XENE trades at $39.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas XENE's P/E ratio is -8.34. In terms of profitability, ELVN's ROE is -0.17%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ELVN is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ELVN vs RYZB Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ELVN's ROE is -0.17%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ELVN is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ELVN vs CBAY Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ELVN's ROE is -0.17%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ELVN is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
ELVN vs AMLX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, AMLX has a market cap of 3.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while AMLX trades at $29.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas AMLX's P/E ratio is -19.68. In terms of profitability, ELVN's ROE is -0.17%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, ELVN is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check AMLX's competition here
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
ELVN vs ACAD Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while ACAD trades at $21.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas ACAD's P/E ratio is 9.56. In terms of profitability, ELVN's ROE is -0.17%, compared to ACAD's ROE of +0.28%. Regarding short-term risk, ELVN is more volatile compared to ACAD. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check ACAD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ELVN vs IOVA Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while IOVA trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas IOVA's P/E ratio is -11.01. In terms of profitability, ELVN's ROE is -0.17%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, ELVN is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check IOVA's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ELVN vs TNGX Comparison November 2026
Enliven Therapeutics, Inc. (NASDAQ: ELVN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ELVN stands at 3.6B. In comparison, TNGX has a market cap of 3.6B. Regarding current trading prices, ELVN is priced at $49.43 on the NASDAQ, while TNGX trades at $21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ELVN currently has a P/E ratio of -29.63, whereas TNGX's P/E ratio is -25.89. In terms of profitability, ELVN's ROE is -0.17%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ELVN is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for ELVN.Check TNGX's competition here